Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elixcyte in Knee Osteoarthritis
NCT02784964Phase 2Completed
- Sponsor
- UnicoCell Biomed Co., Ltd.
- Start
- Mar 2016
- Primary completion
- Jul 2018
- Modality
- Patient-derived iPSCs, Allogeneic iPSCs
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of elixcyte in knee osteoarthritis (OA) (4 arms), sponsored by UnicoCell Biomed Co., Ltd. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index Pain Score at 24 weeks and Incidence of Adverse Events and Serious Adverse Events at 48 weeks. Started Mar 2016; status: completed.
02
Drugs
elixcyte
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT02784964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784964.